Beam Therapeutics (NASDAQ: BEAM) revenue
Beam Therapeutics reported revenue of $139.7m for fiscal 2025, 120.0% more than in fiscal 2024 ($63.5m). Since fiscal 2019 its revenue has grown by 776,250.0%, an average growth of 345.0% a year.
Beam Therapeutics's best year of the last 7 was fiscal 2023. The biggest drop was in fiscal 2024, −83.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $139.7m | +120.0% | −$383.7m | −274.6% |
| 2024 | $63.5m | −83.2% | −$415.6m | −654.3% |
| 2023 | $377.7m | +520.0% | −$176.5m | −46.7% |
| 2022 | $60.9m | +17.5% | −$338.5m | −555.6% |
| 2021 | $51.8m | +215,916.7% | −$392.5m | −757.0% |
| 2020 | $0.0m | +33.3% | −$132.8m | −553,166.7% |
| 2019 | $0.0m | — | −$75.2m | −417,522.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Beam Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Beam Therapeutics ranks 267th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Beam Therapeutics, 120.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 265th | Karyopharm Therapeutics | $146.1m | 0.6% |
| 266th | InfuSystem | $143.4m | 6.4% |
| 267th | Beam Therapeutics | $139.7m | 120.0% |
| 268th | SPOK | $139.7m | 1.5% |
| 269th | Quanterix | $138.9m | 1.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Beam Therapeutics
- How much revenue did Beam Therapeutics make in fiscal 2025?
- Beam Therapeutics reported revenue of $139.7m for fiscal 2025, compared with $63.5m in fiscal 2024.
- How much has the revenue of Beam Therapeutics grown?
- Between fiscal 2019 and fiscal 2025 it went from $0.0m to $139.7m: 776,250.0% more, an average growth of 345.0% a year.
- What was the best year for revenue at Beam Therapeutics?
- Of its last 7 fiscal years, fiscal 2023, with $377.7m.
- Where does Beam Therapeutics rank in its sector by revenue?
- It ranks 267th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Beam Therapeutics come from?
- From the annual report (Form 10-K) that Beam Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Beam Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Beam Therapeutics: the Beam Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.